{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:46:26Z","timestamp":1780454786463,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T00:00:00Z","timestamp":1455148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T00:00:00Z","timestamp":1455148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>Background<\/jats:italic> BTH1677 is a beta glucan pathogen associated molecular pattern (PAMP) currently being investigated as a novel cancer therapy. Here, the initial safety and pharmacokinetic (PK) results of BTH1677 in healthy subjects are reported. <jats:italic>Subjects and Methods<\/jats:italic> In the Phase 1a single-dosing study, subjects were randomized (3:1 per cohort) to a single intravenous (iv) infusion of BTH1677 at 0.5, 1, 2, 4, or 6\u00a0mg\/kg or placebo, respectively. In the Phase 1b multi-dosing study, subjects were randomized (3:1 per cohort) to 7 daily iv infusions of BTH1677 at 1, 2, or 4\u00a0mg\/kg or placebo, respectively. Safety and PK non-compartmental analyses were performed. <jats:italic>Results<\/jats:italic> Thirty-six subjects (<jats:italic>N<\/jats:italic>\u00a0=\u00a024 Phase 1a; <jats:italic>N<\/jats:italic>\u00a0=\u00a012 Phase 1b) were randomized to treatment. No deaths or serious adverse events occurred in either study. Mild or moderate adverse events (AEs) occurred in 67\u00a0% of BTH1677-treated subjects in both studies. Treatment-related AEs (occurring in \u226510\u00a0% of subjects) included dyspnea, flushing, headache, nausea, paraesthesia, and rash in Phase 1a and conjunctivitis and headache in Phase 1b. BTH1677 serum concentration was linear with dose. Clearance, serum elimination half-life (t<jats:sub>1\/2<\/jats:sub>) and volume of distribution (Vss) were BTH1677 dose-independent. In Phase 1b, area under the curve, t<jats:sub>1\/2<\/jats:sub>, and Vss values were larger at steady state on days 6\u201330 versus day 0. <jats:italic>Conclusions<\/jats:italic> BTH1677 was well tolerated after single doses up to 6\u00a0mg\/kg and after 7 daily doses up to 4\u00a0mg\/kg.<\/jats:p>","DOI":"10.1007\/s10637-016-0325-z","type":"journal-article","created":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T02:56:24Z","timestamp":1455159384000},"page":"202-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3\u20131,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects"],"prefix":"10.1007","volume":"34","author":[{"given":"C. E.","family":"Halstenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Shamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Gargano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. M.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Patchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,11]]},"reference":[{"key":"325_CR1","volume-title":"Chemistry, biochemistry, and biology of (1-\u00a0>\u00a03)-\u00df-glucans and related polysaccharides","author":"A Bacic","year":"2009","unstructured":"Bacic A, Fincher G, Stone B (2009) Chemistry, biochemistry, and biology of (1-\u00a0>\u00a03)-\u00df-glucans and related polysaccharides. Academic Press-Elsevier Inc, New York"},{"key":"325_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nri2939","volume":"11","author":"R Luigina","year":"2011","unstructured":"Luigina R (2011) Immunity to fungal infections. Nat Rev Immunol 11:275\u2013288","journal-title":"Nat Rev Immunol"},{"key":"325_CR3","doi-asserted-by":"crossref","unstructured":"Sorrell T, Chen S (2009) Fungal-derived immune modulating molecules. Adv Exp Med Biol 666:108\u2013120","DOI":"10.1007\/978-1-4419-1601-3_9"},{"key":"325_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fimmu.2013.00230","volume":"4","author":"N Bose","year":"2013","unstructured":"Bose N, Chan A, Guerrero F, Maristany C, Qui X, Walsh R, Ertelt K, Jonas A, Gorden K, Dudney C, Wurst L, Danielson M, Elmasry N, Magee A, Patchen M, Vasilakos J (2013) Binding of soluble yeast beta-glucan to human neutrophils and monocytes is complement-dependent. Front Immunol 4:230","journal-title":"Front Immunol"},{"key":"325_CR5","volume-title":"Imprime PGG, a yeast beta-glucan immunomodulator, can engage Fc gamma receptor (FcgR) in addition to complement receptor 3 (CR3) on human neutrophils and monocytes (abstract)","author":"A Jonas","year":"2015","unstructured":"Jonas A, Qiu X, Chan A, McMurray D, Bose N (2015) Imprime PGG, a yeast beta-glucan immunomodulator, can engage Fc gamma receptor (FcgR) in addition to complement receptor 3 (CR3) on human neutrophils and monocytes (abstract). Keystone Symposium on Tumor Immunology, Multidisciplinary Science Driving Combination Therapy, Banff, Alberta"},{"issue":"15S","key":"325_CR6","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1200\/jco.2014.32.15_suppl.3045","volume":"13","author":"N Bose","year":"2014","unstructured":"Bose N, Antonysamy M, Patchen M, Lowe J, Mattson P, Gargano M, Gordon K, Leonardo S, Walsh R, Qui X, McMurry D, Chan A, Jonas A, Huhn R, Thomas M, Sadjadian P, Schneller F (2014) Endogenous anti-beta-glucan antibodies as a potential predictive biomarker for clinical resposne to imprime PGG immunotherapy in non-small cell lung cancer (NSCLC) patients (abstract). J Clin Oncol 13(15S):3045","journal-title":"J Clin Oncol"},{"key":"325_CR7","doi-asserted-by":"crossref","unstructured":"Bose N, Jonas A, Qiu X, Chan A, Ottoson N, Graff J (2015c) Imprime PGG treatment enhances antibody-dependent cellular phagocytosis (ADCP) of tumor cells by monocyte-derived macrophages (abstract). AACR the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR15-A015"},{"key":"325_CR8","doi-asserted-by":"crossref","unstructured":"Leonardo S, Fulton R, Wurst L, Gorden K, Jonas A, Qui X, Chan A, Graff J (2015a) Imprime PGG binds to neutrophils through complement, Fc, and dectin-1 receptors, priming these cells for enhanced ROS production and tumor cell cytotoxicity (abstract). AACR the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR15-A160"},{"issue":"Suppl 3","key":"325_CR9","doi-asserted-by":"publisher","first-page":"P191","DOI":"10.1186\/2051-1426-2-S3-P191","volume":"2","author":"A Chan","year":"2014","unstructured":"Chan A, Qiu X, Bykowski Jonas A, Patchen M, Bose N (2014) Imprime PGG, a yeast beta glucan immunomodulator, has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype (abstract). J Immunother Cancer 2(Suppl 3):P191","journal-title":"J Immunother Cancer"},{"issue":"Suppl 15","key":"325_CR10","doi-asserted-by":"publisher","first-page":"LB225","DOI":"10.1158\/1538-7445.AM2015-LB-225","volume":"75","author":"A Chan","year":"2015","unstructured":"Chan A, Qiu X, Bykowski Jonas A, Kangas T, Ottoson N, Bose N (2015) Imprime PGG modulates the function of monocyte-derived M2 macrophages and dendritic cells to drive T cell expansion (abstract). Cancer Res 75(Suppl 15):LB225","journal-title":"Cancer Res"},{"key":"325_CR11","volume-title":"Imprime PGG modulates the myeloid component of the tumor microenvironment to coordinate an anti-tumor immune response (abstract). AACR international conference on frontiers in basic cancer research","author":"K Fraser","year":"2015","unstructured":"Fraser K, Ottoson N, Qiu X, Chan A, Bykowski Jonas A, Kangas T, Graff J, Bose N (2015) Imprime PGG modulates the myeloid component of the tumor microenvironment to coordinate an anti-tumor immune response (abstract). AACR international conference on frontiers in basic cancer research. PA, Philadelphia"},{"issue":"Suppl 15","key":"325_CR12","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/1538-7445.AM2015-5034","volume":"75","author":"S Leonardo","year":"2015","unstructured":"Leonardo S, Fulton R, Wurst L, Gorden K (2015b) Imprime PGG decreases regulatory T cell suppression and enhances T cell proliferation and differentiation revealing additional mechanisms for its anti-tumor activity (abstract). Cancer Res 75(Suppl 15):5034","journal-title":"Cancer Res"},{"key":"325_CR13","unstructured":"Bose N, Fulton R, Chan A, Leonardo S, Fraser K, Jonas A, Ottoson N, Qiu X, Gorden K, Graff J (2015a) Imprime PGG, a yeast-derived Pathogen-Associated Molecular Pattern (PAMP), drives a coordinated anti-cancer immune attack (abstract). Symposia on Cancer Research: Emerging Concepts in Host Response to Cancer, Houston, TX"},{"key":"325_CR14","doi-asserted-by":"crossref","unstructured":"Bose N, Chan A, Jonas A, Qiu X, Ottoson N, Kangas T, Graff J (2015b) Imprime PGG treatment elicits a coordinated antitumor immune response that triggers enhanced expression of PD-L1 on tumor cells as well as monocyte-derived macrophages and dendritic cells. Cancer Res 75 (Suppl 15):LB-228","DOI":"10.1158\/1538-7445.AM2015-LB-228"},{"key":"325_CR15","doi-asserted-by":"crossref","unstructured":"Fulton R, Leonardo S, Michel K, Danielson M, Gorden K, Graff J (2015) Imprime PGG, a soluble beta-glucan, binds to and activate dendritic cells resulting in enhanced T cell priming, expansion, and cytokine production (abstract). AACR the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, Philadelphia, PA","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR15-B019"},{"key":"325_CR16","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.4049\/jimmunol.177.3.1661","volume":"177","author":"B Li","year":"2006","unstructured":"Li B, Allendorf DJ, Hansen R, Marroquin J, Ding C, Cramer DE, Yan J (2006) Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol 177:1661\u20131669","journal-title":"J Immunol"},{"key":"325_CR17","doi-asserted-by":"publisher","first-page":"6825","DOI":"10.1182\/blood-2011-02-339812","volume":"117","author":"C Qi","year":"2011","unstructured":"Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JR, Yan J (2011) Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans. Blood 117:6825\u20136836","journal-title":"Blood"},{"key":"325_CR18","doi-asserted-by":"publisher","first-page":"7421","DOI":"10.1158\/0008-5472.CAN-07-1465","volume":"67","author":"B Li","year":"2007","unstructured":"Li B, Allendorf DJ, Hansen R, Marroquin J, Cramer DE, Harris CL, Yan J (2007) Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res 67:7421\u20137430","journal-title":"Cancer Res"},{"key":"325_CR19","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1158\/1078-0432.CCR-07-1669","volume":"14","author":"C Salvador","year":"2008","unstructured":"Salvador C, Li B, Hansen R, Cramer DE, Kong M, Yan J (2008) Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Cancer Res 14:1239\u20131247","journal-title":"Clin Cancer Res"},{"key":"325_CR20","doi-asserted-by":"crossref","unstructured":"Zhong W, Hansen R, Li B, Cai Y, Salvador C, Moore G, Yan J (2009) Effect of yeast-derived beta glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models. J Immunother 32:703\u2013712","DOI":"10.1097\/CJI.0b013e3181ad3fcf"},{"key":"325_CR21","volume-title":"Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers","author":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)","year":"2005","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2005) Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Rockville, MD USA"},{"issue":"Suppl 8","key":"325_CR22","first-page":"4584","volume":"21","author":"M Tamayo","year":"2010","unstructured":"Tamayo M, Cornelio G, Bautista J (2010) Safety, pharmacokinetics (PK), and efficacy of imprime PGG plus cetuximab (cetux) with and without irinotecan (irino) in advanced metastatic colorectal cancer (mCRC) patients (abstract). Ann Oncol 21(Suppl 8):4584","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"325_CR23","volume":"22","author":"N Segal","year":"2011","unstructured":"Segal N, Senzer N, Gada P (2011) Imprime PGG plus cetuximab therapy for advanced KRAS mutant colorectal cancer (abstract). Ann Oncol 22(Suppl 5):PD0013","journal-title":"Ann Oncol"},{"issue":"Suppl 14","key":"325_CR24","first-page":"S40","volume":"9","author":"F Schneller","year":"2014","unstructured":"Schneller F, Thomas M, Sadjadian P, Kollmeier J, Bose N, Antonysamy M, Patchen M, Lowe J, Mattson P, Huhn R (2014) PGG beta glucan with carboplatin, paclitaxel and cetuximab for chemoimmunotherapy of advanced non-small cell lung cancer (NSCLC) (abstract). J Thorac Oncol 9(Suppl 14):S40","journal-title":"J Thorac Oncol"},{"issue":"Suppl 2","key":"325_CR25","first-page":"S642","volume":"10","author":"W Engel-Reidel","year":"2015","unstructured":"Engel-Reidel W, Schneller F, Wolf M, Schuette W, Lowe J, Mattson P, Gargano M, Patchen M, Huhn R, Ma B, Braun A (2015) Imprime PGG, a novel immune modulator, combined with carboplatin, paclitaxel and bevacizumab for 1st line advanced nonsquamous NSCLC (abstract). J Thorac Oncol 10(Suppl 2):S642","journal-title":"J Thorac Oncol"},{"key":"325_CR26","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.3109\/10428194.2015.1016932","volume":"56","author":"CS Zent","year":"2015","unstructured":"Zent CS, Call TG, Bowen DA, Conte MJ, LaPlant BR, Witzig TE, Ansell SM, Weiner GJ (2015) Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1\u20136)-beta-glucotriosyl-(1\u20133)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates. Leuk Lymphoma 56:2373\u20132378","journal-title":"Leuk Lymphoma"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0325-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-016-0325-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0325-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0325-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:52:30Z","timestamp":1678510350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-016-0325-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,11]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1007\/s10637-016-0325-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,11]]},"assertion":[{"value":"2 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MA Gargano, ML Patchen and RM Walsh are employed in leadership roles at Biothera Pharmaceutical Inc. and own stock\/stock options in Biothera Pharmaceutical Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was funded by Biothera Pharmaceutical Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}